MLDL1278A clinical trials
Also written MLDL1278A and Orticumab.
How each study uses MLDL1278A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MLDL1278A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Abcentra (2) · Genentech, Inc. (1) · BioInvent International AB (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MLDL1278A.
- Feb 2027Focused Orticumab Research for Treating Inflammation in Coronary ArteriesPhase 2 · Abcentra
Studies
Open first, then newest update. How each study uses MLDL1278A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Focused Orticumab Research for Treating Inflammation in Coronary ArteriesRecruitingPhase 2AbcentraNCT06927739Written as Orticumab
- A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk FactorsCompletedPhase 2AbcentraNCT04776629Written as Orticumab
- A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)CompletedPhase 2Genentech, Inc.NCT01258907Written as MLDL1278A
- Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy SubjectsCompletedPhase 1BioInvent International ABNCT01486823Written as MLDL1278A
Codes
What other systems call MLDL1278A · ClinicalTrials.gg INT000375
- MeSH (NLM) C000604072MLDL1278AOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604072 | MLDL1278A | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.